258 related articles for article (PubMed ID: 32071183)
1. Patient burden and clinical advances associated with postapproval monotherapy cancer drug trials: a retrospective cohort study.
Carlisle BG; Doussau A; Kimmelman J
BMJ Open; 2020 Feb; 10(2):e034306. PubMed ID: 32071183
[TBL] [Abstract][Full Text] [Related]
2. Benefit, burden, and impact for a cohort of post-approval cancer combination trials.
Carlisle BG; Doussau A; Kimmelman J
Clin Trials; 2020 Feb; 17(1):18-29. PubMed ID: 31580145
[TBL] [Abstract][Full Text] [Related]
3. Diminishing clinical impact for post-approval cancer clinical trials: A retrospective cohort study.
Ouimet C; Bouche G; Kimmelman J
PLoS One; 2022; 17(9):e0274115. PubMed ID: 36094914
[TBL] [Abstract][Full Text] [Related]
4. Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study.
Gyawali B; Rome BN; Kesselheim AS
BMJ; 2021 Sep; 374():n1959. PubMed ID: 34497044
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments.
Skydel JJ; Luxkaranayagam AT; Dhruva SS; Ross JS; Wallach JD
JAMA Netw Open; 2019 May; 2(5):e193410. PubMed ID: 31074812
[TBL] [Abstract][Full Text] [Related]
6. Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration.
Hutchinson N; Carlisle B; Doussau A; Bosan R; Gumnit E; MacPherson A; Fergusson DA; Kimmelman J
JAMA Netw Open; 2021 May; 4(5):e2110456. PubMed ID: 34003270
[TBL] [Abstract][Full Text] [Related]
7. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review.
Pease AM; Krumholz HM; Downing NS; Aminawung JA; Shah ND; Ross JS
BMJ; 2017 May; 357():j1680. PubMed ID: 28468750
[No Abstract] [Full Text] [Related]
8. Large numbers of patients are needed to obtain additional approvals for new cancer drugs: A retrospective cohort study.
Ouimet C; Hutchinson N; Wang C; Matyka C; Del Paggio JC; Kimmelman J
Sci Rep; 2023 Sep; 13(1):16138. PubMed ID: 37752147
[TBL] [Abstract][Full Text] [Related]
9. Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis.
Naci H; Zhang Y; Woloshin S; Guan X; Xu Z; Wagner AK
Lancet Oncol; 2024 Jun; 25(6):760-769. PubMed ID: 38754451
[TBL] [Abstract][Full Text] [Related]
10. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
[TBL] [Abstract][Full Text] [Related]
11. Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study.
Wagner J; Marquart J; Ruby J; Lammers A; Mailankody S; Kaestner V; Prasad V
BMJ; 2018 Mar; 360():k668. PubMed ID: 29514787
[TBL] [Abstract][Full Text] [Related]
12. Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials.
Shepshelovich D; Tibau A; Goldvaser H; Molto C; Ocana A; Seruga B; Amir E
J Clin Oncol; 2018 Jun; 36(18):1798-1804. PubMed ID: 29641296
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration.
Naci H; Smalley KR; Kesselheim AS
JAMA; 2017 Aug; 318(7):626-636. PubMed ID: 28810023
[TBL] [Abstract][Full Text] [Related]
14. US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018.
Omae K; Onishi A; Sahker E; Furukawa TA
JAMA Netw Open; 2022 Sep; 5(9):e2230973. PubMed ID: 36083581
[TBL] [Abstract][Full Text] [Related]
15. Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved.
Zhang SX; Fergusson D; Kimmelman J
J Natl Cancer Inst; 2020 Sep; 112(9):886-892. PubMed ID: 32239146
[TBL] [Abstract][Full Text] [Related]
16. National Comprehensive Cancer Network Guideline Recommendations of Cancer Drugs With Accelerated Approval.
Cliff ERS; Rome RS; Kesselheim AS; Rome BN
JAMA Netw Open; 2023 Nov; 6(11):e2343285. PubMed ID: 37962889
[TBL] [Abstract][Full Text] [Related]
17. An estimate of rate of deviation from NCCN guideline recommendations for central nervous system imaging in trials forming basis for drug approval in first line advanced non-small cell lung cancer (NSCLC).
Sharp J; Prasad V
BMC Cancer; 2022 Jan; 22(1):70. PubMed ID: 35034621
[TBL] [Abstract][Full Text] [Related]
18. Characterization of accelerated approval status, trial endpoints and results, and recommendations in guidelines for oncology drug treatments from the National Comprehensive Cancer Network: cross sectional study.
Mooghali M; Mitchell AP; Skydel JJ; Ross JS; Wallach JD; Ramachandran R
BMJ Med; 2024; 3(1):e000802. PubMed ID: 38596814
[TBL] [Abstract][Full Text] [Related]
19. Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021.
Michaeli DT; Michaeli T
J Clin Oncol; 2022 Dec; 40(35):4095-4106. PubMed ID: 35921606
[TBL] [Abstract][Full Text] [Related]
20. Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021.
Benjamin DJ; Xu A; Lythgoe MP; Prasad V
JAMA Netw Open; 2022 Mar; 5(3):e222265. PubMed ID: 35289858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
